Open Access

Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis

  • Authors:
    • Zhuang Liu
    • Changhua Wu
    • Dan Song
    • Liang Wang
    • Jing Li
    • Changfeng Wang
    • Lei Guo
  • View Affiliations

  • Published online on: June 5, 2020     https://doi.org/10.3892/etm.2020.8842
  • Pages: 1644-1652
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Infantile haemangioma (IH) is a benign vascular tumour type that occurs in 3‑10% of infants. In the present meta‑analysis, previous studies comparing clinical outcomes, including the recovery rate and haemangioma activity score (HAS), adverse effects and relapse rates, were compared between patients treated with atenolol and those treated with propranolol for IH. A systematic search in various databases, including Medline, Cochrane Controlled Register of Trials, ScienceDirect and Google Scholar from inception until July 2019 was performed. The Cochrane risk of bias tool was used to assess the quality of published trials. A meta‑analysis with a random‑effects model and reported pooled mean differences (MD) or odds ratios (OR) with 95% CIs was performed. In total, 8 studies including 608 participants were analyzed. Only 2 studies were randomized controlled trials, while the majority of studies had low or unclear bias risks. Except for the response to medication (pooled OR=1.49; 95% CI, 0.85‑2.18), all other outcomes (HAS, adverse reactions and relapse rate) were better for the atenolol group than the propranolol group. Atenolol resulted in better HAS (pooled MD=0.16; 95% CI, ‑0.42 to 0.73). Propranolol had more adverse reactions (pooled OR=2.17; 95% CI, 0.93‑5.06) and a higher relapse rate (pooled OR, 1.67; 95% CI, 0.44‑6.41) when compared to atenolol. However, these findings were not statistically significant. The results of this analysis suggest that atenolol may be non‑inferior to propranolol and may offer advantages, including lower adverse reactions and relapse rates.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Liu, Z., Wu, C., Song, D., Wang, L., Li, J., Wang, C., & Guo, L. (2020). Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis. Experimental and Therapeutic Medicine, 20, 1644-1652. https://doi.org/10.3892/etm.2020.8842
MLA
Liu, Z., Wu, C., Song, D., Wang, L., Li, J., Wang, C., Guo, L."Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis". Experimental and Therapeutic Medicine 20.2 (2020): 1644-1652.
Chicago
Liu, Z., Wu, C., Song, D., Wang, L., Li, J., Wang, C., Guo, L."Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta‑analysis". Experimental and Therapeutic Medicine 20, no. 2 (2020): 1644-1652. https://doi.org/10.3892/etm.2020.8842